Rite Aid Beats On Q3; Widens FY23 Loss Forecast Citing Headwinds

Loading...
Loading...
  • Rite Aid Corp RAD has reported Q3 FY23 sales of $6.08 billion, compared to $6.23 billion a year ago, beating the consensus of $5.94 billion. 
  • The decline was primarily due to a reduction in revenue from COVID vaccines and testing, store closures, and a planned loss of covered lives at Elixir, partially offset by increases in comparable front-end sales and non-COVID prescriptions.
  • The company reported an Adjusted EPS loss of $(0.14) compared to an income of $0.15 a year ago and a consensus loss of $(0.31)
  • Retail Pharmacy Segment revenues decreased 0.5% Y/Y to $4.41 billion.
  • Total same-store prescriptions, excluding COVID immunizations, increased 3.6%, with same-store maintenance prescriptions increasing 2.1% and other same-store acute prescriptions increasing 8%.
  • Pharmacy Services Segment revenues declined 7.1% to $1.73 billion.
  • Guidance: Rite Aid has narrowed its FY23 sales outlook to $23.7-$24.0 billion from $23.6-$24.0 billion expected earlier and a consensus of $23.73 billion.
  • The company expects Retail Pharmacy Segment revenue of $17.4-$17.6 billion and Pharmacy Services Segment revenue of $6.3-$6.4 billion.
  • Rite Aid forecasts adjusted EBITDA of $410-$440 million versus prior guidance of $450-$490 million due to expectations of lower pharmacy margins, cautious consumer demand, and the related impact on seasonal markdowns and continued shrink expense.
  • Adjusted EPS loss is expected to be $(2.18)- $(1.78) up from $(1.52) - $(0.97) forecasted earlier and the consensus of $(1.78).
  • Price Action: RAD stock is up 3.85% at $4.58 during the premarket session on the last check Wednesday.
  • Photo Via Company
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EarningsNewsPenny StocksGuidanceHealth CareMoversTrading IdeasGeneralBriefspremarket tradingwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...